Exact Sciences supplies Oncotype DX breast tests to the King's Lynn trust
- The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust
- East of England
- Call-off from a framework agreement
- 1 April 2024 to 31 March 2027
The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust buys the Oncotype DX Breast Recurrence Score Test from Exact Sciences. The genomic test is run in a laboratory and reports a recurrence score, which helps clinicians choose treatment for breast cancer patients.
The trust ordered the tests as a call-off from a framework agreement. The £189,540 contract runs for three years, from April 2024 to March 2027.
Contract ends March 2027
- What
- Pathology and specialist laboratory testing services
- Supplier
- Exact Sciences
- Value
- £189,540
- How it was bought
- Call-off from a framework agreement
- Dates and next
- Apr 2024 to Mar 2027